The efficacy of Micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents

Japanese Journal of Chemotherapy

Volumn 54, Issue 2, 2006, Pages 125-128

  Ishikawa, Takahiko ^a   Takata, Tohru ^a   Tomoyose, Takeaki ^b   Masuda, Masato ^b   Nakachi, Sawako ^b   Koga, Shin ^c,g   Tsukada, Junichi ^d   Matsuura, Ai ^d   Utsunomiya, Atae ^e   Saburi, Yoshio ^f   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^c Amakusa Chuo General Hospital   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e IMAMURA BUN IN HOSPITAL   (Japan)

^f OITA PREFECTURAL HOSPITAL   (Japan)

^g UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Empiric therapy; Febrile neutropenia; Micafungin

Indexed keywords

ANTIINFECTIVE AGENT; MICAFUNGIN;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMAGING SYSTEM; LABORATORY TEST; LIVER INJURY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SOLID TUMOR;

EID: 33645757752     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Tamura K, Matsuoka H, Tsukada J, et al: Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: Comparative study. Am J Hematol 71: 248-255, 2002
2. Hughes W T, Armstrong D, Bodey G P, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751, 2002
3. Walsh T J, Teppler H, Donowitz G R, et al: Caspo-fungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl Med 351: 1391-1402, 2004
4. van Burik J A, Ratanatharathorn V, Stepan D E, et al: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39: 1407-1416, 2004
5. Chinese source. p. 17, 2003
6. Klastersky J, Paesmans M, Rubenstein E B, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051, 2000
7. Tawara S, Ikeda F, Maki K, et al: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44: 57-62, 2000